DexCom shares dropped 6.0% on Friday, November 6, 2026, a session in which the S&P 500 added 0.3%. The DexCom stock slide came without any announcement, earnings release or regulatory filing from the glucose-monitoring company. Instead, it lined up with steep declines at two diabetes-technology peers, Insulet and Tandem Diabetes Care.
A Peer-Driven Move
The clearest catalyst sat outside DexCom’s own disclosures. Tandem Diabetes Care, which reported 14% revenue growth for its third quarter, used the same earnings call to announce a chief executive change. A call summary published November 6 also noted that a slower-than-expected transition to pharmacy distribution could weigh on Tandem’s revenue growth in 2027.
DexCom sells into the same diabetes market, and its devices operate alongside insulin pumps. On its October 29 call, management said the G7 15 Day system has offered broad pump connectivity since the summer.
The shared market exposure showed up in the trading tape. Insulet fell 6.2% and Tandem lost 6.0%, both close to DexCom’s own decline. Abbott Laboratories and Medtronic retreated by smaller margins, while Senseonics Holdings was the only peer in the group to finish higher.
No Sector-Wide Spillover
The damage did not broaden into health care or the wider market. XLV, the exchange-traded fund tracking the sector, slipped just 0.1%, and the Nasdaq Composite gained 1.1%. The selling was concentrated in DexCom and a handful of diabetes-focused peers rather than spread across the sector.
Where the Numbers Stand
A 6% single-session decline is unusual for DexCom. Only one other session in the prior 365 days produced a move of that size. Swings of this magnitude in either direction have been more frequent, with eight over that span. The stock rose 6.6% on November 4, then gave back 4.5% on November 5, the session before the latest drop.
Despite the recent volatility, DexCom shares returned 34.0% over the trailing twelve months, compared with 9.8% for the S&P 500. The lowest close in that period was $54.84 on November 10, 2025, and the highest was $92.34 on August 21, 2026. Over the past three months, the stock lost 9.4% while the S&P 500 fell 4.6%.
DexCom also carries a richer sales multiple than the broad market. It trades at 5.8 times trailing twelve-month revenue, versus 3.1 times for the S&P 500.
The U.S. Business in Focus
Most of DexCom’s revenue comes from the United States, which generated $970 million of the $1.34 billion booked in the third quarter. U.S. revenue grew 14% year over year, and management said the company continued to gain share in that market.
DexCom is scheduled to report fiscal fourth-quarter 2026 results in February 2027. Management’s guidance points to revenue growth of about 10% at the midpoint for that quarter, down from total revenue growth of 11% in the third quarter. That figure is likely to draw attention when the results arrive.
